Health & Environmental Research Online (HERO)


Print Feedback Export to File
3164966 
Journal Article 
Analysis of adverse events of bevacizumab-containing systemic chemotherapy for metastatic colorectal cancer in Japan 
Isobe, T; Uchino, K; Makiyama, C; Ariyama, H; Arita, S; Tamura, S; Komoda, M; Kusaba, H; Shirakawa, T; Esaki, T; Mitsugi, K; Takaishi, S; Akashi, K; Baba, E 
2014 
Yes 
Anticancer Research
ISSN: 0250-7005
EISSN: 1791-7530 
34 
4 
2035-2040 
English 
24692744 
BACKGROUND: Bevacizumab (BV) is widely used in chemotherapy for metastatic colorectal cancer (mCRC). Although specific adverse events have been observed, their risk factors have not been clarified.

PATIENTS AND METHODS: 178 mCRC patients who underwent chemotherapy were retrospectively examined and correlations between possible risk factors and adverse events were analyzed.

RESULTS: 87 out of 178 patients were treated with BV-containing chemotherapy. Possible risk factors for BV-related adverse events were: remaining primary tumor, current bleeding, history of arterial thromboembolism (ATE), hypertension, and proteinuria, and these were observed in 22%, 2%, 7%, 16%, and 8% of patients, respectively. Patients with hypertension prior to chemotherapy developed significantly worse hypertension (p=0.018). Gastrointestinal bleeding occurred in 3 out of 18 patients with residual primary tumor (16.7%) and 6 out of 63 patients with no primary tumor (8.7%) (p=0.385).

CONCLUSION: Pre-existing hypertension appears to be a risk factor for BV-related deterioration of hypertension.